Stockscreener 앱 받기
69.54
0.44%
0.30
시간 외 거래:
69.70
0.16
+0.23%
Dexcom Inc 주식(DXCM)의 최신 뉴스
DexCom Stock Declines Following Strong Preliminary Q4 Results - TradingView — Track All Markets
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now - TradingView — Track All Markets
MGO One Seven LLC Buys 14,699 Shares of DexCom, Inc. $DXCM - MarketBeat
How Do Investors Really Feel About DexCom Inc? - Benzinga
Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights - marketscreener.com
Dexcom CEO Talks G8 CGM Sensor - Medical Device and Diagnostic industry
DexCom's Q4 2025 Earnings: What to Expect - inkl
Dexcom’s new CEO talks affordability, over-the-counter glucose sensors - Healthcare Brew
DexCom (DXCM) Releases Preliminary, Unaudited Results for Q4 2025 - Insider Monkey
New Dexcom CEO Jake Leach talks 2026 roadmap, next-gen tech - MassDevice
Dexcom’s Jake Leach on the future of continuous glucose monitoring - Modern Healthcare News
Is DexCom (DXCM) Pricing Justified After Recent Multi Year Share Price Weakness - Yahoo Finance
RWC Asset Management LLP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Bought by PKO Investment Management Joint Stock Co - MarketBeat
JPM26: Dexcom’s new CEO eyes international CGM markets for 2026 growth - Yahoo Finance
GRIMES & Co WEALTH MANAGEMENT LLC Sells 17,554 Shares of DexCom, Inc. $DXCM - MarketBeat
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance By Investing.com - Investing.com Nigeria
Barclays Downgrades DexCom (DXCM), Lowers Price Target to $71.00 - GuruFocus
Why This Medical Device Company Is the Top Stock in the S&P 500 Today - Barron's
Dexcom reports 13% rise in preliminary Q4 revenue, issues 2026 outlook - MSN
Why DexCom Is the Top Stock in the S&P 500 Today - Barron's
Barclays Downgrades DexCom to Underweight From Equal Weight, Adjusts Price Target to $71 From $80 - marketscreener.com
DexCom (DXCM) Reports Strong Preliminary Q4 and FY 2025 Revenue Growth - GuruFocus
Dexcom Updates Fiscal 2025 Revenue Guidance; Sets 2026 Outlook - marketscreener.com
Dexcom reports 13% revenue growth in Q4, reiterates 2025 guidance - Investing.com
(DXCM) DexCom Expects 2026 Total Revenue Range $5.16B$5.25B, vs. FactSet Est of $5.23B - marketscreener.com
Glucose monitor maker Dexcom's prelim Q4 revenue beats expectations on G7 15 Day launch - TradingView — Track All Markets
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook - Business Wire
DexCom, Inc. (DXCM) Investor Outlook: 26.63% Potential Upside And Strong Buy Ratings - DirectorsTalk Interviews
Assessing DexCom (DXCM) Valuation As Analyst Actions And Conference Spotlight Shape Sentiment - simplywall.st
DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus
Mizuho Adjusts Price Target on DexCom to $78 From $75, Maintains Outperform Rating - marketscreener.com
Bernstein Adjusts Price Target on DexCom to $86 From $84, Maintains Outperform Rating - marketscreener.com
Robeco Institutional Asset Management B.V. Lowers Stock Holdings in DexCom, Inc. $DXCM - MarketBeat
Why Dexcom (DXCM) Is Up 5.6% After Naming New CEO And Advancing AI Diabetes Platform - Sahm
How DexCom Inc. stock compares to growth peersMarket Movement Recap & Low Risk High Reward Ideas - Улправда
Will DexCom Inc. stock benefit from sector rotationTrade Entry Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
DexCom (DXCM) Stock Falls as Analysts Adjust Price Targets | Jan 2026News and Statistics - IndexBox
How DexCom Inc. stock performs in weak economyTake Profit & Safe Capital Growth Stock Tips - ulpravda.ru
Dexcom Finishes Off Class Claims Over Sales Growth Statements - Bloomberg Law News
DexCom (DXCM) Stock Trades Down, Here Is Why - Finviz
Why DexCom Inc. stock is rated strong buyTreasury Yields & Reliable Volume Spike Trade Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:15 - Улправда
Is DexCom Inc. stock a good choice for value investorsVolume Spike & Short-Term Trading Opportunity Alerts - ulpravda.ru
Moran Wealth Management LLC Grows Stake in DexCom, Inc. $DXCM - MarketBeat
Dexcom CEO Jake Leach begins tenure with focus on metabolic health - Investing.com Nigeria
Dexcom CEO Jake Leach Takes the Helm, Presents Future at CES - Medical Product Outsourcing
Dexcom enters next era of continued innovation with Jake Leach as chief executive officer - marketscreener.com
Dexcom CEO Jake Leach begins tenure with focus on metabolic health By Investing.com - Investing.com South Africa
Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer - DexCom Investor Relations
Is DexCom, Inc.'s (NASDAQ:DXCM) Recent Stock Performance Tethered To Its Strong Fundamentals? - 富途牛牛
DexCom Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
UBS (AMUB) DexCom-linked trigger autocallable notes detail coupons and downside risk - Stock Titan
Dexcom Inc. Bets Big on Continuous Glucose Monitoring — and It’s Winning - AD HOC NEWS
Why pension funds invest in DexCom Inc. (DC4) stock2026 world cup usa national team qualification defensive leaders high defensive line knockout prediction preview - ulpravda.ru
Dexcom Lawsuits - Consumer Notice
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
How DexCom Inc stock performs in weak economy2025 Performance Recap & AI Enhanced Trading Signals - moha.gov.vn
Dexcom names Jacob Leach as incoming chief executive - MSN
Assessing DexCom (DXCM) Valuation As Shares Lag Over The Past Year - Yahoo Finance
DexCom, Inc.'s (NASDAQ:DXCM) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
0.22%
2.02%
자본화:
|
볼륨(24시간):